GlobalHealth Threats

The World Health Organization (WHO) has requested manufacturers of mpox in vitro diagnostics (IVDs) to submit expressions of interest for Emergency Use Listing (EUL). This request follows ongoing discussions with manufacturers about the need for effective diagnostics, especially in low-income settings. The aim is to improve testing availability, which is crucial for early treatment and controlling the spread of mpox. Since 2022, WHO has distributed approximately 150,000 diagnostic tests worldwide, with over a quarter sent to the African Region. An additional 30,000 tests are scheduled for delivery to African countries in the coming weeks.

In response to the significant rise in suspected mpox cases, particularly in the Democratic Republic of the Congo, WHO has enhanced diagnostic capabilities by equipping six additional labs and decentralising testing to affected provinces. The update to diagnostic testing guidance includes methods to detect new viral strains, such as clade Ib. WHO’s Emergency Use Listing procedure will facilitate the procurement of needed diagnostic tests and other medical products, ensuring timely access and effective response to the outbreak.